TH1902 PDC: The next glorious destination for conjugated drugs?
TH1902
SORT1, also known as neurotensin receptor 3, is a membrane-bound receptor that belongs to the VPS10P receptor family. SORT1 plays different roles in transporting and sorting various ligands (including neurotensin, progranulin, and apolipoprotein E) into the cell. On the other hand, the upregulation of SORT1 has also been observed in many types of human cancers, such as breast cancer, ovarian cancer, pancreatic cancer and melanoma, as well as pituitary adenomas. In particular, SORT1 is expressed in 59% of TNBC, which can also make it a therapeutic target for TNBC. Thera technologies developed the PDC drug TH1902 for the SORT1 receptor. In terms of the structure of the drug, TH1902 should be regarded as a conventional conjugated drug form. At present, TH1902 has entered clinical phase I study, and early safety and efficacy data are planned to be released in Q4. In early 2021, the FDA also granted fast track certification for TH1902 single-agent treatment of sortilin-positive recurrent advanced solid tumors refractory to standard therapies.
The peptide molecule in TH1902 can target the SORT1 protein expressed in a variety of cancers, and the cleavable Linker links the peptide with the toxic load docetaxel…
In addition to the ADC drug boom, more conjugated drugs have yet to show real clinical breakthroughs. Compared with other conjugate drugs, several peptide nuclide conjugate drugs have been marketed in the PDC field, which is considered to be a good performance. Possibly, PDC drugs will develop more rapidly only after more representative drugs have self-certified value. After all, compared with other conjugated drugs, the technological and production advantages of peptide drugs are destined to have a broader industrial foundation for PDC drugs.
https://m.gelonghui.com/p/482098